INVESTMENTS - RELATED PARTIES (Tables)

9 Months Ended

Sep. 30, 2020

Investments, Debt and Equity Securities [Abstract]

Schedule of investments

Investments in AVLP and Alzamend Neuro, Inc. (“Alzamend”) at September 30, 2020 and December 31, 2019, are comprised of the following:

	September 30,			December 31,
	2020			2019
Investment in convertible promissory note of AVLP	$	10,153,661		$	9,595,079
Investment in convertible promissory note of Alzamend		50,000			—
Accrued interest in convertible promissory note of AVLP		2,025,475			2,025,475
Total investment in convertible promissory note of AVLP – Gross		12,229,136			11,620,554
Less: original issue discount		(9,904	)		—
Less: provision for loan losses		(5,159,910	)		(5,079,834	)
Total investment in convertible promissory note of AVLP and Alzamend		7,059,322			6,540,720
Investment in derivative instruments of AVLP		2,490,794			1,330,684
Investment in common stock of AVLP		259,786			238,602
Investment in common stock and warrants of Alzamend		587,686			558,938
Investment in derivative instruments and common stock of AVLP and Alzamend		3,338,266			2,128,224
Total investment in AVLP and Alzamend – Net	$	10,397,588		$	8,668,944
Investment in warrants and common stock of AVLP and Alzamend	$	3,338,266		$	2,128,224
Investment in convertible promissory note of AVLP and Alzamend		7,059,322			6,540,720
Total investment in AVLP and Alzamend – Net	$	10,397,588		$	8,668,944

Schedule of summarizes the changes in our investments

The following table summarizes the changes in our investments in AVLP and Alzamend during the nine months ended September 30, 2020:

	Investment in		Investment in
	warrants and		convertible		Total
	common stock		promissory		investment
	of AVLP and		note of AVLP		in AVLP and
	Alzamend		and Alzamend		Alzamend – Net
Balance at January 1, 2020	$	2,128,224	$	6,540,720	$	8,668,944
Investment in convertible promissory notes of AVLP		—		478,506		478,506
Investment in convertible promissory note of Alzamend		—		38,128		38,128
Investment in common stock of AVLP and Alzamend		12,884		—		12,884
Investment in warrants of Alzamend		11,872		—		11,872
Fair value of derivative instruments issued by AVLP		80,076		—		80,076
Unrealized loss in derivative instruments of AVLP		1,080,034		—		1,080,034
Unrealized loss in common stock of AVLP and Alzamend		25,176		—		25,176
Accretion of discount				1,968		1,968
Balance at September 30, 2020	$	3,338,266	$	7,059,322	$	10,397,588